Lupin is currently trading at Rs. 939.45, up by 55.35 points or 6.26% from its previous closing of Rs. 884.10 on the BSE.
The scrip opened at Rs. 890.00 and has touched a high and low of Rs. 972.50 and Rs. 882.55 respectively. So far 310410 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.05 on 07-Dec-2021.
Last one week high and low of the scrip stood at Rs. 972.50 and Rs. 870.00 respectively. The current market cap of the company is Rs. 40366.54 crore.
The promoters holding in the company stood at 46.83%, while Institutions and Non-Institutions held 40.41% and 12.76% respectively.
Lupin has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The company has committed to manufacture and supply products of the highest quality from all manufacturing sites.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.